# Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer

> **NCT03349203** · PHASE2 · UNKNOWN · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- EGF-R Positive Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Icotinib

## Key facts

- **NCT ID:** NCT03349203
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-01
- **Primary completion:** 2022-02-01
- **Final completion:** 2023-12-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2018-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03349203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03349203, "Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03349203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*